<DOC>
	<DOCNO>NCT03016806</DOCNO>
	<brief_summary>This study single-center , treatment protocol 4 possible preparative regimen , design validate process umbilical cord blood stem cell transplantation institution .</brief_summary>
	<brief_title>Combined Cord Blood Transplant</brief_title>
	<detailed_description>This study single-center treatment protocol four possible preparative regimen , design validate process umbilical cord blood stem cell transplantation institution . Enrolled patient receive chemotherapy +/-total body radiation pre-transplant conditioning regimen . Patients receive cord blood stem cell follow GvHD prophylaxis include Tacrolimus Mycophenolate Mofetil , Cyclosporin A Methylprednisolone . Multiple data point collect prior , , g follow transplantation ensure safety process evaluate state objective .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Appropriate diagnosis : Patients must disease syndrome amenable therapy hematopoietic stem cell transplantation . Diagnoses include , limited : Congenital Other Nonmalignant Disorders : Immunodeficiency disorder ( e.g . Severe Combined Immunodeficiency , WiskottAldrich Syndrome ) Congenital hematopoietic stem cell defect ( e.g . ChediakHigashi Syndrome , Congenital Osteopetrosis , Osteogenesis Imperfecta ) Metabolic disorder ( e.g . Hurler 's Syndrome ) Severe aplastic anemia HighRisk Leukemia : Acute Myelogenous Leukemia Refractory standard induction therapy ( 1 cycle require achieve remission ) Recurrent ( CR ≥ 2 ) Treatmentrelated AML MDS Evolved myelodysplastic syndrome Presence FLT3 abnormalities FAB M6 M7 Adverse cytogenetics Myelodysplastic Syndrome Acute Lymphoblastic Leukemia include T lymphoblastic leukemia : Refractory standard induction therapy ( time CR &gt; 4 week ) Recurrent ( CR ≥ 2 ) WBC count &gt; 30,000/mcL diagnosis Age &gt; 30 diagnosis Adverse cytogenetics , ( 9:22 ) , ( 1:19 ) , ( 4:11 ) , MLL rearrangement . Chronic Myelogenous Leukemia accelerate phase blast crisis Biphenotypic undifferentiated leukemia Burkitt 's leukemia lymphoma Lymphoma : Large cell , Mantle cell , Hodgkin lymphoma refractory recurrent , chemosensitive , ineligible autologous stem cell transplant previously treat autologous SCT Marginal zone follicular lymphoma progressive least two prior therapy Multiple Myeloma , recurrent follow highdose therapy autologous SCT ineligible autologous HSCT Solid tumor , efficacy allogeneic HSCT demonstrate specific disease disease status Adequate organ function : Cardiac LVEF &gt; 45 % , shorten fraction &gt; 25 % , Absence congestive heart failure conduction disturbance high risk sudden death Pulmonary DLCO ( correct hemoglobin ) , FEV1 FVC ≥ 50 % predict ; Renal serum Cr &lt; 1.5 time upper limit normal age GFR ≥ 50 ml/min/1.73m2 Hepatic total bilirubin level &lt; 2 time upper limit normal ( except patient Gilbert 's syndrome hemolysis ) ; primary disease process causal , criterion reconsider . ALT , AST , Alkaline phosphatase ≤ 5 time upper limit normal . Performance Status Karnofsky Lansky score ≥ 70 % . Informed Consent must obtain prior initiate condition therapy . Receipt viable cord blood product ( ) , single dual , must confirm stem cell process laboratory prior initiate condition therapy . Availability 10/10 9/10 HLAmatched relate unrelated donor within reasonable timeframe dictate clinical urgency transplant Autologous HSCT &lt; 6 month prior propose UCB transplant Pregnant breast feed Current uncontrolled infection Evidence HIV infection positive HIV serology</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>